Upcoming conferences

January 5, 2026

Our CEO will be attending the 1st Annual European Neuroscience Innovation Forum on March 3rd, 2026 in Zurich.

Amyl has been selected for 2 on site presentations at ADPD 2026 conference that will take place on March 17-21, 2026 in Copenhagen.

“Next-generation neurodegenerative diseases therapeutics with strong binding for amyloid-β/tau/𝛼-synuclein aggregates, reduced risk of aria, and improved brain delivery.“

Presenter: Damien Toulorge, CSO
Date and time: Thursday 19th March 09h40-09h55
Room: Hall 180-181
Session name: 5255 – Machanistic modifiers of AD: APOE, Immunity, and neural circuits (ID 424)

“Crossing molecular boundaries: an immunotherapeutic simultaneously targeting amyloid-β, tau and 𝛼-synuclein amyloid aggregates”.

Presenter: Aditya Iyer, Senior Project Manager
Date and time: Saturday 21st March 18h15-18h30
Room: Hall A2
Session name: 6130 – Tau, Amyloid, and synuclein: mechanisms and treatments (ID 142)

Our CEO will be attending the Neuroscience of Vitality and Aging (NOVA) Conference on April 25th, 2026 in Boston.

Our Senior Project Manager, Aditya Iyer, will be attending the Alzheimer Society International Congress (ASIC) on May 18-20, 2026 in San Francisco.

About Merieux Equity Partners

Mérieux Equity Partners (MxEP) is an AMF-accredited management company dedicated to equity investments in healthcare. MxEP actively supports entrepreneurs and companies with differentiated products and services, giving them privileged access to its sector expertise and international network. MxEP currently manages c.€1.5bn ($1.6bn) AUM.

www.merieux-partners.com

About Noshaq Partners

Noshaq is a Belgian investment fund and project developer with a portfolio of 477 companies. Noshaq is the reference financial partner for the creation and development of SMEs in the Liege region (Wallonia). Over the years, it has developed a range of financing vehicles in line with the needs and trends of the market and its strategy. Each service offered by Noshaq (capital – loan – leasing) is always determined according to the demands and needs of the owner-investor. Its objective is always to have a leverage effect on the company’s development.

www.noshaq.be

About Sambrinvest

With over 35 years of experience working alongside companies and entrepreneurs, more than 280 portfolio companies and 170 million euros in assets under management, Sambrinvest is a major venture capital player in Wallonia. More than an investment fund, Sambrinvest is also a catalyst for the development of local ecosystems, such as biotech, digital and engineering.

www.sambrinvest.be